Bupropion for the treatment of methamphetamine dependence in non-daily users: a randomized, double-blind, placebo-controlled trial.

ABSTRACT:

Aim

Bupropion was tested for efficacy to achieve methamphetamine (MA) abstinence in dependent, non-daily users.

Methods

A randomized, double-blind, placebo-controlled trial, with 12-week treatment and 4-week follow-up, was conducted with 204 treatment-seeking participants having MA dependence per DSM-IV, who used MA on a less-than-daily basis. 104 were randomized to matched placebo and 100 to bupropion, sustained-release 150mg, twice daily. Participants were seen three times weekly to obtain urine for MA and bupropion assays, study assessments, and thrice weekly, 90-min, group psychotherapy. There was no biomarker for placebo adherence. The primary outcome was achievement of abstinence throughout the last two weeks of treatment; 'success' requiring at least two urine samples

SUBMITTER: Anderson AL 

PROVIDER: S-EPMC4388163 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature